Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$24.37 +0.2%	$19.47	$16.10 ▼ $41.94	$3.08B	0.78	2.90 million shs	1.34 million shs
DNLI Denali Therapeutics	$13.96 -1.9%	$14.30	$10.57 ▼ $33.33	$2.03B	1.36	1.66 million shs	2.20 million shs
IOVA Iovance Biotherapeutics	$2.11 -20.1%	$2.22	$1.64 ▼ $12.51	$704.60M	0.88	26.31 million shs	43.40 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	0.00%	+6.19%	+24.78%	+40.87%	-27.45%
DNLI Denali Therapeutics	0.00%	+3.87%	-9.06%	-2.99%	-35.61%
IOVA Iovance Biotherapeutics	0.00%	-21.27%	+9.33%	+20.57%	-71.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.7054 of 5 stars	4.3	3.0	4.4	3.8	2.5	0.6
DNLI Denali Therapeutics	4.2084 of 5 stars	3.6	1.0	4.7	3.8	3.3	0.0
IOVA Iovance Biotherapeutics	4.66 of 5 stars	4.2	1.0	4.2	2.8	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.58	Moderate Buy	$34.12	40.00% Upside
DNLI Denali Therapeutics	3.12	Buy	$33.85	142.45% Upside
IOVA Iovance Biotherapeutics	2.38	Hold	$11.90	463.98% Upside

Current Analyst Ratings Breakdown

Latest DNLI, APLS, and IOVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	IOVA Iovance Biotherapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$18.00 ➝ $14.00
8/8/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $20.00
8/4/2025	APLS Apellis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$35.00 ➝ $37.00
8/1/2025	APLS Apellis Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$17.00 ➝ $19.00
8/1/2025	APLS Apellis Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$39.00 ➝ $40.00
8/1/2025	APLS Apellis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$52.00 ➝ $50.00
7/29/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$41.00 ➝ $46.00
7/28/2025	DNLI Denali Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/23/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/18/2025	APLS Apellis Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$47.00 ➝ $50.00
7/16/2025	APLS Apellis Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00

(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$754.65M	4.08	N/A	N/A	$1.24 per share	19.65
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	$8.53 per share	N/A
IOVA Iovance Biotherapeutics	$241.53M	2.92	N/A	N/A	$2.33 per share	0.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.82	N/A	N/A	N/A	-30.24%	-116.09%	-26.72%	N/A
DNLI Denali Therapeutics	-$422.77M	-$2.67	N/A	N/A	N/A	N/A	-35.90%	-32.41%	N/A
IOVA Iovance Biotherapeutics	-$372.18M	-$1.23	N/A	N/A	N/A	-161.44%	-51.95%	-40.78%	N/A

Latest DNLI, APLS, and IOVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	IOVA Iovance Biotherapeutics	-$0.29	-$0.33	-$0.04	-$0.33	$67.14 million	$59.95 million
7/31/2025	Q2 2025	APLS Apellis Pharmaceuticals	-$0.44	-$0.33	+$0.11	-$0.33	$187.91 million	$171.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.90	3.77	3.16
DNLI Denali Therapeutics	N/A	9.56	9.56
IOVA Iovance Biotherapeutics	N/A	4.18	3.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
DNLI Denali Therapeutics	92.92%
IOVA Iovance Biotherapeutics	77.03%

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.50%
DNLI Denali Therapeutics	12.50%
IOVA Iovance Biotherapeutics	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	126.29 million	118.08 million	Optionable
DNLI Denali Therapeutics	430	145.28 million	127.12 million	Optionable
IOVA Iovance Biotherapeutics	500	333.93 million	299.54 million	Optionable

DNLI, APLS, and IOVA Headlines

Recent News About These Companies

Truist Financial Keeps Their Hold Rating on Iovance Biotherapeutics (IOVA)

August 10 at 5:01 AM | theglobeandmail.com

Iovance Biotherapeutics Second Quarter 2025 Earnings: Misses Expectations

August 9 at 6:53 PM | finance.yahoo.com

Iovance Biotherapeutics (NASDAQ:IOVA) Given New $14.00 Price Target at Wells Fargo & Company

August 9 at 11:43 AM | marketbeat.com

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Down on Disappointing Earnings

August 9 at 10:47 AM | marketbeat.com

Chardan Capital Lowers Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $20.00

August 9 at 9:10 AM | marketbeat.com

3 Stocks That Could Turn $1,000 Into $5,000 by 2030

August 9 at 4:21 AM | fool.com

Iovance cuts staff amid slow sales start for ‘TIL’ cell therapy

August 8 at 10:13 PM | finance.yahoo.com

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025

August 8 at 10:13 PM | tmcnet.com

Iovance Biotherapeutics price target lowered to $14 from $18 at Wells Fargo

August 8 at 10:13 PM | msn.com

Iovance Bio updates on Amtagvi

August 8 at 10:13 PM | thepharmaletter.comT

Iovance falls after missing Q2 expectation

August 8 at 10:13 PM | msn.com

Bay Area biotech company once worth $4.4 billion lays off chunk of staff

August 8 at 10:13 PM | msn.com

Iovance Biotherapeutics Stock Falls as 2Q Results Miss Analyst Estimates

August 8 at 10:13 PM | marketwatch.com

Why Iovance Biotherapeutics Stock Plummeted Today

August 8 at 7:31 PM | fool.com

IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi

August 8 at 1:51 PM | zacks.com

Iovance Biotherapeutics, Inc. (IOVA) Q2 2025 Earnings Call Transcript

August 8 at 4:01 AM | seekingalpha.com

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates

August 7 at 6:10 PM | zacks.com

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025

August 7 at 4:01 PM | globenewswire.com

CM Management LLC Acquires 200,000 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

August 7 at 6:19 AM | marketbeat.com

XTX Topco Ltd Purchases New Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

August 6, 2025 | marketbeat.com

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Up - What's Next?

August 5, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI, APLS, and IOVA Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$24.37 +0.04 (+0.16%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$23.70 -0.68 (-2.77%)

As of 08/8/2025 07:49 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Denali Therapeutics NASDAQ:DNLI

$13.96 -0.27 (-1.90%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$13.88 -0.08 (-0.54%)

As of 08/8/2025 07:35 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Iovance Biotherapeutics NASDAQ:IOVA

$2.11 -0.53 (-20.08%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$2.10 0.00 (-0.24%)

As of 08/8/2025 07:58 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time